Scientists reprogram stem cells in mice

Blood stem cells sit at the top of the immune system’s family tree. If you can rewrite them, you’re not just tweaking one batch of cells — you’re changing the pipeline that keeps making new ones. That is the basic idea behind a new mouse study from Harald Hartweger, Michel Nussenzweig, and colleagues at Rockefeller University. They used CRISPR to edit hematopoietic stem and progenitor cells, then showed those edited cells could give rise to B cells that made protective antibodies for the long haul in mice. (science.org) ### What did they actually change? They inserted antibody instructions directly into the immunoglobulin locus of blood-forming stem and precursor cells — the genomic neighborhood B cells normally use to make antibodies. After those edited cells were transplanted into mice, they matured into B lymphocytes already set up to express the chosen antibody, plus in some cases an extra protein cargo. (science.org)m cells? Because mature B cells burn out. Researchers have already shown that you can edit B cells themselves, but those responses fade as the cells die off. Stem cells are different — they keep producing fresh descendants. So if the edit lands upstream, the body can keep replenishing engineered B cells instead of running through a one-time supply. (the-scientist.com)4368)) ### Why is HIV part of this story? HIV is the classic hard target for vaccines. The best antibodies against it are broadly neutralizing antibodies, or bNAbs, and they are rare because they usually need unusual precursor cells and a long stretch of mutation and selection before they become potent. That makes HIV a good stress test for any platform that tries to manufacture hard-to-eliciting antibodies on purpose. (science.org) ### What happened in the mice? The edited stem cells produced B cells that were quiet at first but could be amplified by immunization with the matching antigen. Once the mice got that antigen exposure, serum antibody levels rose to high, long-lasting levels, and booster immunizations pushed them higher. In an influenza challenge model, the antibodies were protective enough to shield mice from lethal viral infection. (science.org) ### What is the most striking detail? Scale. The team reported that roughly 7,000 edited hematopoietic stem and progenitor cells were enough to reach therapeutic antibody levels. That matters because stem-cell editing is never perfectly efficient, so a platform that works with very small numbers looks much more realistic than one that needs massive engraftment. They also showed combinations of edited stem cells could make multiple antibodies against the same target at once. (science.org) ### Is this only about antibodies? Probably not. The paper frames the system more broadly as a protein-production platform. In plain English, the immune system becomes a living bioreactor. Instead of giving repeated infusions of a therapeutic protein, you try to install the instructions once and let immune cells keep making it. That is why the authors and outside coverage point to possible uses beyond infection — inc(science.org)d cancer. (rockefeller.edu) ### So are humans next? Not fast. This is still a mouse proof of concept, and it used transplantation of edited stem cells rather than a simple in-body shot. The catch is that stem-cell editing, engraftment, safety, dose control, and off-target risks all get harder in humans. But the conceptual jump is real — the work shows immune engineering can move upstream from temporary cell edits to a renewable source of antibody-making cells. (science.org) ### Bottom line? The news is not that scientists cured HIV or built a cancer treatment. The news is that they showed a small number of edited blood stem cells can seed a durable, boostable antibody response in mice. Basically, they turned part of the immune system into programmable infrastructure — and that opens a much bigger door than a one-off antibody shot. (science.org)